Bringing Connected Drug Discovery Together Under One Name

For more than 20 years, Sygnature Discovery has partnered with biotech and pharmaceutical companies to solve complex scientific challenges. While many recognise us for our strong roots in chemistry, the way we work today reflects something much broader: connected, multidisciplinary drug discovery, designed to deliver speed without compromising on quality.

Our refreshed brand reinforces who we are now, a global drug discovery partner supporting customers across Europe, North America and beyond, with scientists working side by side to make better decisions, faster.

“This isn’t about changing who we are,” says Dr. Simon Hirst, CEO of Sygnature Discovery. “It’s about clearly expressing the capability and expertise we’ve built, and the way our teams work together to deliver for our customers today.”

A connected approach, built around collaboration

For many years, our model has been built on close collaboration between disciplines, guided by a simple belief: the best science happens when experts work together, not in silos.

At Sygnature, chemists understand how to work with and innovate alongside biologists. Biologists work hand in hand with DMPK and in vivo experts. Decisions are shaped collectively, using shared data and insight, rather than being passed between disconnected teams.

As we’ve grown, we’ve deliberately built capabilities around this way of working. Through continued investment and strategic acquisitions, we’ve expanded the breadth and depth of our expertise while staying true to our hands-on, collaborative approach.

“We’ve grown significantly in scale and capability over the past two decades,” Simon explains. “But our focus has always been the same, building teams and environments that help scientists collaborate effectively and solve problems faster.”

Working across two continents, under one roof

Many organisations talk about integrated drug discovery. In practice, this often means handing work between teams, locations, or even different companies.

Our model is different.

At Sygnature, our scientists work in the same labs, in real time. Multidisciplinary teams are co-located, sharing data, challenging assumptions, and solving problems together as projects evolve.

We operate three fully co-located drug discovery hubs in the UK and North America, bringing a variety of disciplines together under one roof. And with no competing internal programs, we offer total confidentiality and commitment.

“This way of working reduces inertia and build momentum,” says Simon. “By co-locating disciplines, we accelerate feedback loops and improve decision making earlier in the process, which ultimately helps our customers move faster with greater confidence.”

Connecting the full DMTA cycle

A cornerstone of our approach is the ability to deliver the full Design, Make, Test, Analyze (DMTA) cycle in a connected way across both Europe and North America.

By linking these stages of discovery, rather than treating them as separate steps, our teams can iterate more quickly, identify risk earlier, and make better informed decisions at every stage.

“Working with fewer partners reduces complexity,” Simon notes. “It helps customers move faster and increases the quality of the output, without compromising scientific rigour.”

This approach supports customers looking for end-to-end programmes, as well as those who need specialist expertise in a specific discipline.

Expertise enhanced by AI and automation

Scientific expertise sits at the heart of everything we do. Increasingly, that expertise is supported by data, AI and automation, embedded across our workflows.

These capabilities enhance how our teams design experiments, analyze data, and make decisions, helping us move faster while maintaining high scientific standards.

“Technology doesn’t replace expertise,” says Simon. “It strengthens it, enabling our teams to generate better insight, more efficiently, and with greater confidence.”

Built around how our customers work

Our customers come to us with different needs, from biotechs seeking support across discovery, to pharmaceutical companies looking for deep expertise in a specific area.

Our connected, collaborative model is designed to support both, underpinned by a commitment to integrity, openness, and partnership.

“Whether customers need full programmes or specialist support, we work as an extension of their team,” Simon adds. “That means open communication, constructive challenge, and a shared focus on success.”

A connected future for drug discovery

Our refreshed brand amplifies a model that’s already well established, connecting our people, capabilities, and global footprint under one identity.

“Ultimately, our goal is simple,” Simon concludes. “To help our customers make better decisions, faster, and build the foundations for successful medicines.”

Sygnature Discovery. Beyond Boundaries.